Pacific Biosciences of California | DEFA14A: Others
Pacific Biosciences of California | DEF 14A: Definitive information statements
Pacific Biosciences of California | 8-K: PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Schedul
Pacific Biosciences of California | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Pacific Biosciences of California | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Pacific Biosciences of California | 8-K: PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
Pacific Biosciences of California | 8-K: Current report
Pacific Biosciences of California | 8-K: Current report
Pacific Biosciences of California | 8-K: PacBio Announces Third Quarter 2023 Financial Results
Pacific Biosciences of California | 8-K/A: Current report (Amendment)
Pacific Biosciences of California | 8-K: Current report
Pacific Biosciences of California | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Pacific Biosciences of California | 8-K/A: Current report (Amendment)
Pacific Biosciences of California | 8-K: PacBio Announces Second Quarter 2023 Financial Results
Pacific Biosciences of California | 8-K: Current report
Pacific Biosciences of California | 8-K: Current report
Pacific Biosciences of California | 8-K: Current report
Pacific Biosciences of California | 8-K: Current report
Pacific Biosciences of California | DEFA14A: Others
Pacific Biosciences of California | DEF 14A: Definitive proxy statements
No Data